IE60991B1 - Use of ketone derivatives in the treatment of cognitive disorders - Google Patents

Use of ketone derivatives in the treatment of cognitive disorders

Info

Publication number
IE60991B1
IE60991B1 IE341487A IE341487A IE60991B1 IE 60991 B1 IE60991 B1 IE 60991B1 IE 341487 A IE341487 A IE 341487A IE 341487 A IE341487 A IE 341487A IE 60991 B1 IE60991 B1 IE 60991B1
Authority
IE
Ireland
Prior art keywords
methyl
use according
treatment
medicament
manufacture
Prior art date
Application number
IE341487A
Other languages
English (en)
Other versions
IE873414L (en
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630075A external-priority patent/GB8630075D0/en
Priority claimed from GB878726424A external-priority patent/GB8726424D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IE873414L publication Critical patent/IE873414L/xx
Publication of IE60991B1 publication Critical patent/IE60991B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IE341487A 1986-12-17 1987-12-16 Use of ketone derivatives in the treatment of cognitive disorders IE60991B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB868630075A GB8630075D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878726424A GB8726424D0 (en) 1987-11-11 1987-11-11 Medicaments

Publications (2)

Publication Number Publication Date
IE873414L IE873414L (en) 1988-06-17
IE60991B1 true IE60991B1 (en) 1994-09-07

Family

ID=26291706

Family Applications (1)

Application Number Title Priority Date Filing Date
IE341487A IE60991B1 (en) 1986-12-17 1987-12-16 Use of ketone derivatives in the treatment of cognitive disorders

Country Status (15)

Country Link
US (1) US4845115A (US06566495-20030520-M00011.png)
EP (1) EP0275668B1 (US06566495-20030520-M00011.png)
JP (1) JP2608078B2 (US06566495-20030520-M00011.png)
KR (1) KR950013450B1 (US06566495-20030520-M00011.png)
AU (1) AU618520B2 (US06566495-20030520-M00011.png)
CY (1) CY1692A (US06566495-20030520-M00011.png)
DE (1) DE3782028T2 (US06566495-20030520-M00011.png)
DK (1) DK662687A (US06566495-20030520-M00011.png)
ES (1) ES2052585T3 (US06566495-20030520-M00011.png)
GR (1) GR3006255T3 (US06566495-20030520-M00011.png)
HK (1) HK36693A (US06566495-20030520-M00011.png)
IE (1) IE60991B1 (US06566495-20030520-M00011.png)
IL (1) IL84845A0 (US06566495-20030520-M00011.png)
NZ (1) NZ222950A (US06566495-20030520-M00011.png)
PH (1) PH25025A (US06566495-20030520-M00011.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200414A (en) * 1986-12-17 1993-04-06 Glaxo Group Limited Methods for the treatment of cognitive disorders
US5190954A (en) * 1986-12-17 1993-03-02 Glaxo Group Limited Methods for the treatment of cognitive disorders
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
US5229407A (en) * 1988-09-01 1993-07-20 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
EP0492020A1 (en) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Use of certain esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-one and related compounds for treating cognitive disorders
AU2254692A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア，インコーポレーテッド 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
JPH08507514A (ja) * 1993-03-08 1996-08-13 藤沢薬品工業株式会社 脳血管性疾患を治療または予防するための薬物
ZA989365B (en) * 1997-10-15 1999-04-15 Boehringer Mannheim Pharm Corp Preparation for treating alzheimer's disease
TR200101892T2 (tr) * 1999-01-07 2001-11-21 P.N. Gerolymatos S.A. Hafıza bozukluklarının tedavisi veya önlenmesi için fankuinonun kullanımı.
CA2371822A1 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
GB0701970D0 (en) 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
IE57809B1 (en) * 1984-01-25 1993-04-21 Glaxo Group Ltd 1,2,3,9-tetrahydro-3-(imidazol-1-ylmethyl)-4h-carbazol-4 one derivatives
AU583343B2 (en) * 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions

Also Published As

Publication number Publication date
JP2608078B2 (ja) 1997-05-07
AU618520B2 (en) 1992-01-02
IL84845A0 (en) 1988-06-30
KR880007074A (ko) 1988-08-26
CY1692A (en) 1994-01-14
ES2052585T3 (es) 1994-07-16
KR950013450B1 (ko) 1995-11-08
AU8261487A (en) 1988-06-23
JPS63253083A (ja) 1988-10-20
EP0275668A3 (en) 1989-10-11
DK662687A (da) 1988-06-18
NZ222950A (en) 1997-06-24
HK36693A (en) 1993-04-23
GR3006255T3 (US06566495-20030520-M00011.png) 1993-06-21
DK662687D0 (da) 1987-12-16
DE3782028T2 (de) 1993-02-18
PH25025A (en) 1991-01-28
US4845115A (en) 1989-07-04
EP0275668B1 (en) 1992-09-30
EP0275668A2 (en) 1988-07-27
IE873414L (en) 1988-06-17
DE3782028D1 (de) 1992-11-05

Similar Documents

Publication Publication Date Title
US4845115A (en) Method of medical treatment
EP0276559B1 (en) Use of ketone derivatives in the treatment of depression
IE60908B1 (en) Pharmaceutical compositions for treating gastric disorders
US4847281A (en) Method of medical treatment of addiction
CA1330536C (en) Medicament for the treatment of a cognitive disorder
JP2834175B2 (ja) 医 薬
IL95245A (en) Pharmaceutical preparations containing 1,2,3,9, - tetrahydro-9-methyl-3-] 2-methyl-H1-imidazol-1-yl (methyl [-H4- carbazole-4-carbazol-4-one for the treatment of bulimia and
US5229407A (en) Medicaments
CA1330534C (en) Medicament for the treatment of addiction
CA1330535C (en) Medicament for treating depression
EP0269452A2 (en) Use of ketone derivatives for the manufacture of medicaments
US5221687A (en) Medicaments
JPH01250319A (ja) 医薬

Legal Events

Date Code Title Description
MM4A Patent lapsed